The global legalized cannabis market size was valued at USD 42.48 billion in 2025 and is projected to grow from USD 53.10 billion in 2026 to USD 316.50 billion by 2034, registering a CAGR of 25% during the forecast period from 2026 to 2034. North America dominated the legalized cannabis market with a market share of 54.8% in 2025.
Legalized cannabis refers to the legal cultivation, distribution, sale, possession, and consumption of cannabis under government regulations for medical, recreational, or both purposes. Legalization frameworks vary by country and region, establishing rules for licensing, product quality, taxation, and consumer safety. The legalization of cannabis is driving growth in regulated cannabis markets, increasing investments in cultivation, processing, retail, and cannabis-related healthcare products.
Download a Free Sample To learn more about this report,
Expansion of State-Licensed Cannabis Retail Networks
The legalized cannabis market is shifting toward broader and more accessible licensed retail networks as jurisdictions increase the number of approved dispensaries and expand geographic coverage. This is improving consumer access to regulated products and strengthening the commercial infrastructure required for legal-market participation.
Increasing Formalization of Medical Cannabis Regulatory Frameworks
Medical cannabis markets are increasingly being subject to structured regulatory reviews as governments assess how existing frameworks affect patients, healthcare professionals, manufacturers, and importers. This is encouraging greater scrutiny of product access, prescribing arrangements, manufacturing controls, and the long-term role of cannabis-based medicines within healthcare systems.
Growing Acceptance of Cannabis-Based Products Expands the Potential Consumer Base
Changing social attitudes toward cannabis and increasing awareness of its potential medical and wellness applications are broadening the population willing to consider legal cannabis products. Greater familiarity with cannabis-based products for therapeutic and wellness purposes is encouraging consumers to explore different product categories and supporting sustained demand across the legalized cannabis market.
High Tax and Compliance Costs Reduce Price Competitiveness of Licensed Cannabis
Licensed cannabis businesses must absorb costs associated with taxation, licensing, testing, tracking, security, and regulatory compliance. These expenses can increase final product prices relative to unregulated alternatives, making it more difficult for legal operators to compete on price in mature markets.
Development of Cannabis Consumption Areas Creates New Licensed Revenue Channels
Legal markets are expanding beyond conventional dispensary sales by permitting regulated locations where adults can consume cannabis purchased through licensed businesses. These venues create opportunities for retailers and other licensed operators to develop differentiated customer experiences and generate additional commercial activity around legal cannabis consumption.
Competition From Unlicensed Cannabis Sales Continues to Undermine Legal-Market Conversion
Licensed operators continue to compete with businesses selling cannabis outside regulated channels. Unlicensed products can avoid testing, labeling, taxation, and other compliance expenses, creating a price and accessibility advantage that can slow the conversion of consumers from informal markets to regulated purchasing channels.
Medical Segment Dominated the Market with 45.3% Share in 2025
The medical segment dominated the legalized cannabis market with a 45.3% market share in 2025, accounting for USD 19.24 billion, and is projected to grow at a CAGR of 23.1% during the forecast period. The segment's dominance is driven by the increasing use of cannabis for treating chronic pain, epilepsy, multiple sclerosis, chemotherapy-induced nausea, and other medical conditions. Growing physician acceptance, expanding government approvals for medical cannabis programs, and increasing clinical research continue to strengthen the segment's leading position.
The recreational and industrial hemp segments also contribute significantly to the legalized cannabis market. Recreational cannabis is witnessing rapid adoption in regions with legalized adult-use programs, while industrial hemp continues to gain demand for applications in textiles, food products, personal care, and industrial materials.
Request Customizationto receive a tailored report.
Oil Segment is Projected to Register the Fastest Growth at a CAGR of 25.7%
The oil segment is projected to register the fastest CAGR of 25.7% during 2026–2034. The segment accounted for 34.7% of the market, valued at USD 14.74 billion in 2025. Growth is driven by increasing demand for precise dosing, ease of administration, and expanding use of cannabis oils in medical therapies, wellness products, and pharmaceutical formulations. The growing popularity of cannabidiol (CBD) and tetrahydrocannabinol (THC)-based oils is further supporting segment expansion.
The bud and tincture segments continue to maintain a significant presence in the legalized cannabis market. Bud remains the most widely consumed cannabis form due to its traditional use and broad consumer acceptance, while tinctures are gaining popularity because of their convenience, controlled dosage, and increasing adoption in medical applications.
Chronic Pain Segment Dominated the Market with 42.4% Share in 2025
The chronic pain segment dominated the legalized cannabis market with a 42.4% market share in 2025, accounting for USD 18.01 billion, and is projected to grow at a CAGR of 24.2% during the forecast period. The increasing prevalence of chronic pain conditions, growing preference for non-opioid pain management options, and expanding clinical evidence supporting medical cannabis are driving the segment's growth. Healthcare providers are increasingly considering cannabis-based therapies as part of comprehensive pain management strategies.
The mental disorders, cancer, and others segments also account for a significant share of the legalized cannabis market. Rising research into cannabinoid-based treatments for anxiety, depression, cancer symptom management, and other therapeutic applications continues to support demand across these medical indications.
Speak to an Analystto discuss market opportunities.
North America dominated the legalized cannabis market with a 54.8% share in 2025, accounting for USD 23.28 billion, and is projected to grow at a CAGR of 22.6% during the forecast period. Growth is driven by widespread legalization of medical and adult-use cannabis, well-established regulatory frameworks, increasing consumer acceptance, and strong investments in licensed cultivation, processing, and retail infrastructure. Continuous product innovation and expanding retail networks further support regional market growth.
The U.S. market was valued at USD 20.26 billion in 2025, making it the largest contributor in North America. Expanding state-level legalization, increasing demand for medical and recreational cannabis products, growing investments in cultivation facilities, and a strong network of licensed dispensaries continue to drive market growth.
Canada's market reached USD 3.02 billion in 2025. Nationwide cannabis legalization, strong regulatory oversight, increasing product diversification, and rising exports of cannabis products continue to support steady market expansion.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe accounted for 20.7% of the legalized cannabis market, reaching USD 8.79 billion in 2025, and is expected to register a CAGR of 26.4% during the forecast period. The regional market is driven by expanding medical cannabis legalization, increasing pharmaceutical research, and growing government support for regulated cannabis programs. Rising investments in cultivation and processing facilities are further accelerating market growth.
The U.K. market was valued at USD 2.11 billion in 2025. Increasing clinical research, growing demand for cannabis-based medicines, and expanding access to regulated medical cannabis continue to support market growth.
Germany's market accounted for USD 2.64 billion in 2025. Expanding medical cannabis adoption, evolving cannabis regulations, increasing domestic cultivation, and rising investments in pharmaceutical cannabis continue to strengthen market expansion.
Asia Pacific held 14.6% of the legalized cannabis market, valued at USD 6.20 billion in 2025, and is projected to grow at a CAGR of 24.8% during the forecast period. Increasing research into medical cannabis, expanding industrial hemp cultivation, supportive regulatory developments in selected countries, and growing investments in pharmaceutical applications continue to drive regional market growth.
Japan's market generated USD 1.43 billion in 2025. Increasing cannabinoid research, regulatory reforms supporting medical cannabis applications, and rising investments in pharmaceutical innovation continue to support market growth.
China's market accounted for USD 3.22 billion in 2025, representing the largest share within Asia Pacific. Strong industrial hemp production, expanding cannabinoid research, increasing exports of hemp-derived products, and growing investment in cannabis-related biotechnology continue to drive market expansion.
Middle East & Africa accounted for 3.8% of the legalized cannabis market, totaling USD 1.61 billion in 2025, and is anticipated to grow at a CAGR of 20.9% during the forecast period. Increasing legalization for medical and industrial applications, growing pharmaceutical research, and expanding cultivation programs are supporting regional market growth.
The UAE market was valued at USD 0.36 billion in 2025. Growing investments in pharmaceutical research, expanding life sciences infrastructure, and increasing interest in cannabinoid-based therapies continue to drive market growth.
Africa's market reached USD 1.25 billion in 2025. Expanding medical cannabis cultivation, increasing government support for regulated production, rising export opportunities, and growing foreign investments continue to create long-term growth opportunities across the region.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Precision Cardiology Market Size, Share, Growth, Analysis, 2034
Europe Aesthetic Medicine Market Size, Top Share, Forecast ,2034
Latin America Neurodegenerative Diseases Market Includes Latest Trends, 2034
Asia Pacific Neurodegenerative Diseases Market Size, Share by 2034
LAMEA Lidocaine Market Size, Growth , 2026-2034
North America Neurodegenerative Disease Market Size, 2034
We are featured on:
sales@straitsresearch.com